HCV DRAG Definitions Working Group DNWG

This group was conceived at the 5th HCV DRAG meeting in Boston, 2010 is a collaboration between the HCV DRAG, IDSA, EASL and AASLD and will help bring uniformity and clarity to the terms and definitions currently being used in DAA clinical trials. Since the DAA trials field is in its infancy, the WG will regularly update these terms as the field evolves. A manuscript regarding this topic is currently being drafted.

James Appleman, PhD
Anadys Pharmaceuticals, Inc.

Richard Colvin, MD, PhD
Novartis Institutes for BioMedical Research, Inc.

Jordan Feld, MD, MPH
Toronto Western Hospital Liver Center

Xavier Forns, MD, PhD
Hospital Clinic

Patrick Harrington, PhD
U.S. Food and Drug Administration

Gabrielle Heilek, PhD
Roche Molecular Systems

Mingjun Huang, PhD
Achillion Pharmaceuticals, Inc.

Eric Hughes, MD, PhD
Bristol-Myers Squibb

Ira Jacobson, MD
Cornell University

Donald M. Jensen, MD, FACP
University of Chicago Medical Center

Filip Josephson, MD, PhD
Swedish Medical Products Agency/European Medicines

Minhee Kang, PhD
Harvard School of Public Health

Dale Kempf, PhD
Abbott Laboratories

Tara Kieffer, PhD
Vertex Pharmaceuticals

Ann Kwong, PhD
Vertex Pharmaceuticals

Geert Maertens, PhD
Biocartis SA

Nina Mani, PhD, MPH
Forum for Collaborative HIV Research

Veronica Miller, PhD
Forum for Collaborative HIV Research

Jeffrey Murray, MD, MPH
U.S. Food and Drug Administration

Lisa Naeger, PhD
US Food and Drug Administration

Isabel Najera, PhD
Hoffmann La Roche

Gaston Picchio, PhD
Janssen research and Development, LLC